share_log

Morgan Stanley Adjusts Price Target on IO Biotech to $11 From $15, Maintains Overweight Rating

Morgan Stanley Adjusts Price Target on IO Biotech to $11 From $15, Maintains Overweight Rating

摩根士丹利將 IO 生物技術的價格目標從 15 美元調整至 11 美元,維持超重評級
MT Newswires ·  2023/01/24 11:36

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論